De Cremer Kaat, Delattin Nicolas, De Brucker Katrijn, Peeters Annelies, Kucharíková Soña, Gerits Evelien, Verstraeten Natalie, Michiels Jan, Van Dijck Patrick, Cammue Bruno P A, Thevissen Karin
Centre of Microbial and Plant Genetics, KU Leuven, Leuven, Belgium Department of Plant Systems Biology, VIB, Ghent, Belgium.
Centre of Microbial and Plant Genetics, KU Leuven, Leuven, Belgium.
Antimicrob Agents Chemother. 2014 Dec;58(12):7606-10. doi: 10.1128/AAC.03869-14. Epub 2014 Oct 6.
We here report on the in vitro activity of toremifene to inhibit biofilm formation of different fungal and bacterial pathogens, including Candida albicans, Candida glabrata, Candida dubliniensis, Candida krusei, Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis. We validated the in vivo efficacy of orally administered toremifene against C. albicans and S. aureus biofilm formation in a rat subcutaneous catheter model. Combined, our results demonstrate the potential of toremifene as a broad-spectrum oral antibiofilm compound.
我们在此报告托瑞米芬抑制不同真菌和细菌病原体生物膜形成的体外活性,这些病原体包括白色念珠菌、光滑念珠菌、都柏林念珠菌、克柔念珠菌、铜绿假单胞菌、金黄色葡萄球菌和表皮葡萄球菌。我们在大鼠皮下导管模型中验证了口服托瑞米芬对白色念珠菌和金黄色葡萄球菌生物膜形成的体内疗效。综合来看,我们的结果表明托瑞米芬作为一种广谱口服抗生物膜化合物的潜力。